News Column

Study Findings from University of Johannesburg Provide New Insights into Nucleoproteins

May 13, 2014



By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Proteins is now available. According to news reporting originating in Doornfontein, South Africa, by NewsRx journalists, research stated, "The fabrication of a mesoporous silica nanoparticle (MSN)-protamine hybrid system (MSN-PRM) is reported that selectively releases drugs in the presence of specific enzyme triggers present in the proximity of cancer cells. The enzyme trigger involved is a protease called trypsin, which is overexpressed in certain specific pathological conditions, such as inflammation and cancer."

The news reporters obtained a quote from the research from the University of Johannesburg, "Overexpression of trypsin is known to be associated with invasion, metastasis, and growth in several cancers, such as leukemia, colon cancer, and colorectal cancer. The current system (MSN-PRM) consists of an MSN support in which mesopores are capped with an FDA-approved peptide drug protamine, which effectively blocks the outward diffusion of the drug molecules from the mesopores of the MSNs. On exposure to the enzyme trigger, the protamine cap disintegrates, opening up the molecular gates and releasing the entrapped drug molecules. The system exhibits minimal premature release in the absence of the trigger and selectively releases the encapsulated drugs in the presence of the proteases secreted by colorectal cancer cells. The ability of the MSN-PRM particles to deliver anticancer drugs to colorectal cancer cells has also been demonstrated. The hydrophobic drug is released into cancer cells subsequent to disintegration of the protamine cap, resulting in cell death. Drug-induced cell death in colorectal cancer cells is significantly enhanced when the hydrophobic drug that is known to degrade in aqueous environments is encapsulated in the MSN-PRM system in comparison to the free drug (P < 0.05)."

According to the news reporters, the research concluded: "The system, which shows good biocompatibility and selective drug release, is a promising platform for cancer specific drug delivery."

For more information on this research see: Protamine-Capped Mesoporous Silica Nanoparticles for Biologically Triggered Drug Release. Particle & Particle Systems Characterization, 2014;31(4):449-458. Particle & Particle Systems Characterization can be contacted at: Wiley-V C H Verlag Gmbh, Boschstrasse 12, D-69469 Weinheim, Germany. (Wiley-Blackwell - www.wiley.com/; Particle & Particle Systems Characterization - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4117)

Our news correspondents report that additional information may be obtained by contacting K. Radhakrishnan, Univ Johannesburg, Dept. of Appl Chem, ZA-2028 Doornfontein, South Africa. Additional authors for this research include S. Gupta, D.P. Gnanadhas, P.C. Ramamurthy, D. Chakravortty and A.M. Raichur (see also Proteins).

Keywords for this news article include: Cancer, Oncology, Colorectal, Protamines, Doornfontein, South Africa, Nanoparticle, Nanotechnology, Nucleoproteins, Gastroenterology, Nuclear Proteins, Silicon Nanocrystals, Emerging Technologies, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters